YD Bio, EG BioMed Launch AI Cancer Risk Assessment
MT Newswires Live
Oct 06
YD Bio (YDES) said Tuesday it launched along with EG BioMed an AI-powered cancer risk assessment that organizes self-reported health information into personalized reports covering 10 cancer types.
The 52-question assessment takes about 10 minutes and provides low, moderate or high risk stratification based on a 48-feature pan-cancer model and 10 cancer-specific models, YD Bio said.
The service is available in English and Chinese for a promotional price of $10, reduced from $50, the company said.
YD Bio said the tool does not diagnose cancer or replace medical evaluation.
Shares of YD Bio were down 7.7% in premarket activity Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.